Prior information notice
This notice is for prior information only
Section I: Contracting
authority
I.1) Name and addresses
NHS Blood and Transplant
203 Longmead Rd, Avon
Bristol
BS16 7FG
UK
Contact person: Tennille Madigan
Telephone: +44 7795483583
E-mail: tennille.madigan@nhsbt.nhs.uk
NUTS: UKK12
Internet address(es)
Main address: https://www.nhsbt.nhs.uk
Address of the buyer profile: https://www.nhsbt.nhs.uk
I.3) Communication
Additional information can be obtained from the abovementioned address
Electronic communication requires the use of tools and devices that are not generally available. Unrestricted and full direct access to these tools and devices is possible, free of charge, at:
https://health-family.force.com/s/Welcome
I.4) Type of the contracting authority
Body governed by public law
I.5) Main activity
Health
Section II: Object
II.1) Scope of the procurement
II.1.1) Title
Malaria & Arbovirus detection assays
II.1.2) Main CPV code
71900000
II.1.3) Type of contract
Services
II.1.4) Short description
The Kit Evaluation Group (KEG) assesses the suitability of molecular and serological microbiological assays to be used for the screening of blood and non-blood (e.g. stem cell, tissue) donors to ensure assays are suitable in terms of sensitivity and specificity. KEG approval of suitable assays is a requirement of the Guidelines for the Blood Transfusion Services in the United Kingdom (Red Book - https://www.transfusionguidelines.org/red-book).<br/><br/>NHSBT are looking to perform two evaluations, one on malaria detection assays and the other on arbovirus detection assays, which utilise high-throughput automated Nucleic Acid Testing (NAT) technology. This system needs to be integrated (extraction and amplification stages on the same automated equipment) and target DNA or RNA in blood samples collected from blood and non-blood donors. An automated and integrated NAT system is essential to minimise manual steps and to allow for high-throughput testing.<br/><br/>These evaluations are driven by horizon scanning and testing resilience and the proposed work would be standalone evaluations not linked to any procurement exercises. To learn more about KEG we will be holding virtual webinars in the summer of 2024.
II.1.5) Estimated total value
Value excluding VAT:
1.00
GBP
II.1.6) Information about lots
This contract is divided into lots:
No
II.2) Description
II.2.2) Additional CPV code(s)
71900000
33141625
33124130
33696200
II.2.3) Place of performance
NUTS code:
UKK12
Main site or place of performance:
NHS Blood and Transplant Site: Filton
II.2.4) Description of the procurement
The Kit Evaluation Group (KEG) assesses the suitability of molecular and serological microbiological assays to be used for the screening of blood and non-blood (e.g. stem cell, tissue) donors to ensure assays are suitable in terms of sensitivity and specificity. Kit Evaluation Group (KEG) approval of suitable assays is a requirement of the Guidelines for the Blood Transfusion Services in the United Kingdom (Red Book - https://www.transfusionguidelines.org/red-book).<br/><br/>NHSBT are looking to perform two evaluations, one on malaria detection assays and the other on arbovirus detection assays, which utilise high-throughput automated Nucleic Acid Testing (NAT) technology. This system needs to be integrated (extraction and amplification stages on the same automated equipment) and target DNA or RNA in blood samples collected from blood and non-blood donors. An automated and integrated NAT system is essential to minimise manual steps and to allow for high-throughput testing.<br/><br/>These evaluations are driven by horizon scanning and testing resilience and the proposed work would be standalone evaluations not linked to any procurement exercises. To learn more about KEG we will be holding virtual webinars in the summer of 2024. <br/>Please email tennille.madigan@nhsbt.nhs.uk for further information and expressions of interest by 30th April 2024.
II.3) Estimated date of publication of contract notice:
01/07/2024
Section IV: Procedure
IV.1) Description
IV.1.8) Information about Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement:
No
Section VI: Complementary information
VI.5) Date of dispatch of this notice
29/02/2024